GlassScriptPhysician profile
Deborah Darlene Shipman
NPI 1093739286
$41,008.89
in general payments reported to CMS, 2019-2025
19 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $92.81 · 2022: $302 · 2023: $11K · 2024: $29K · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $17K · Honoraria: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,674 · Food and Beverage: $3,895 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $17,144.42 |
| Honoraria | $12,880.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,674.00 |
| Food and Beverage | $3,895.28 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $23,893.79 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $15,078.06 | 2022-2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $344.81 | 2022-2025 | Leqvio |
| Astrazeneca Pharmaceuticals LP | $340.05 | 2024-2025 | Wainua, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $276.97 | 2023-2025 | |
| Scpharmaceuticals INC. | $174.62 | 2024 | |
| Amgen INC. | $131.73 | 2024-2025 | Repatha, Repatha |
| Cvrx, INC. | $121.72 | 2023-2024 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.49 | 2022-2024 | Jardiance |
| Pfizer INC. | $110.80 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $94.07 | 2023-2025 | Camzyos, Eliquis |
| Daxor Corporation | $92.59 | 2024 | Bva-100 |
| Lilly USA, LLC | $90.10 | 2025 | Zepbound |
| Boston Scientific Corporation | $44.89 | 2022 | |
| Becton, Dickinson and Company | $24.00 | 2024 | Site-Rite |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.53 | 2022 | |
| Abiomed | $22.52 | 2024 | Impella |
| Janssen Pharmaceuticals, INC | $14.67 | 2022 | |
| Bridgebio Pharma, INC. | $14.48 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Shipman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.